Assessing proarrhythmic potential of drugs when optimal studies are infeasible-Reference-Cited by-同舟云学术

Assessing proarrhythmic potential of drugs when optimal studies are infeasible

Published:2009-05 Issue:5 Volume:157 Page:827-836.e1
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Rock Edwin P.,Finkle John,Fingert Howard J.,Booth Brian P.,Garnett Christine E.,Grant Stephen,Justice Robert L.,Kovacs Richard J.,Kowey Peter R.,Rodriguez Ignacio,Sanhai Wendy R.,Strnadova Colette,Targum Shari L.,Tsong Yi,Uhl Kathleen,Stockbridge Norman

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference35 articles.

1. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects;Mason;J Electrocardiol,2007

2. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes;Gupta;Am Heart J,2007

3. Torsades de pointes occurring in association with terfenadine use;Monahan;JAMA,1990

4. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes;Loose;J Clin Invest,1983

5. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin;Honig;Clin Pharmacol Ther,1992

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study;Cancer Chemotherapy and Pharmacology;2023-06-27

2. Ventricular Arrhythmia in Cancer Patients: Mechanisms, Treatment Strategies and Future Avenues;Arrhythmia & Electrophysiology Review;2023-05-29

3. Effect of Pevonedistat, an Investigational NEDD8‐Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors;Clinical Pharmacology in Drug Development;2022-11-16

4. Predicting human cardiac QT alterations and pro-arrhythmic effects of compounds with a 3D beating heart-on-chip platform;Toxicological Sciences;2022-10-13

5. Assessment of Effects of Investigational TAK‐931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid Tumors;Clinical Pharmacology in Drug Development;2022-02-20